OncoMatch/Clinical Trials/Penile Cancer
Penile Cancer Clinical Trials
OncoMatch filters Penile Cancer trials by the molecular markers that determine eligibility — CD274, EGFR, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout Penile Cancer trials
Penile cancer is a rare malignancy, most commonly squamous cell carcinoma, with about half of cases linked to human papillomavirus (HPV) infection. PD-L1 (CD274) status is tested for immunotherapy trial eligibility, particularly in advanced disease where IO is an active area of development despite the rarity of the cancer. EGFR is a long-standing target through anti-EGFR antibody approaches (cetuximab and similar) and remains relevant in combination trials.
Trial selection in penile cancer depends on stage, HPV status, and prior platinum exposure. Locally advanced trials test chemoradiation strategies, including organ-preserving approaches that aim to avoid total penectomy and its quality-of-life implications. Metastatic first-line trials center on platinum-based chemotherapy (often TPF: cisplatin + 5-FU + paclitaxel) with IO addition under study. Metastatic later-line trials test IO monotherapy, anti-EGFR combinations, and novel mechanisms in this small but active trial space. HPV-positive penile cancer trials test vaccine strategies and HPV-targeted approaches because of the strong HPV association. HIV-associated penile cancer trials are a distinct subset given the higher prevalence of HPV-positive disease in HIV-positive patients.
Penile cancer trial intake typically checks stage, prior platinum chemotherapy, and HPV status. Stage at enrollment (locally advanced vs metastatic) determines which trial set applies. HPV status (HPV-positive vs HPV-negative) gates HPV-targeted trials and is a stratification factor in some IO trials. Prior platinum chemotherapy exposure for line-specific trials. Prior immunotherapy exposure for IO-rechallenge or post-IO trials. Surgical status (partial vs total penectomy, inguinal lymph node dissection) for trials testing post-operative therapies. HIV status for HIV-associated penile cancer trials. Performance status, with most trials accepting ECOG 0-1.
Biomarkers tested in Penile Cancer trials
These are the molecular markers most commonly required or evaluated in Penile Cancer eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Penile Cancer trials
Ranked by phase and number of US sites. See all trials matched to your profile →
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Institute of Cancer Research, United Kingdom
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Christian Hinrichs
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Mayo Clinic
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Christian Hinrichs
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
How OncoMatch finds Penile Cancer trials for you
AI reads the protocol
Every Penile Cancer trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Penile Cancer and mark your biomarker results — CD274, EGFR — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.